Cohort profile for the STratifying Resilience and Depression Longitudinally (STRADL) study : A depression-focused investigation of Generation Scotland, using detailed clinical, cognitive, and neuroimaging assessments by Habota, Tina et al.
 Open Peer Review
RESEARCH ARTICLE
Cohort profile for the STratifying Resilience and Depression
Longitudinally (STRADL) study: A depression-focused
investigation of Generation Scotland, using detailed clinical,
 cognitive, and neuroimaging assessments [version 1; peer
review: 1 approved, 1 not approved]
Tina Habota ,       Anca-Larisa Sandu , Gordon D. Waiter , Christopher J. McNeil ,
     J. Douglas Steele , Jennifer A. Macfarlane , Heather C. Whalley ,
       Ruth Valentine , Dawn Younie , Nichola Crouch , Emma L. Hawkins ,
       Yoriko Hirose , Liana Romaniuk , Keith Milburn , Gordon Buchan ,
         Tessa Coupar , Mairi Stirling , Baljit Jagpal , Beverly MacLennan , Lucasz Priba ,
       Mathew A. Harris , Jonathan D. Hafferty , Mark J. Adams , Archie I. Campbell ,
       Donald J. MacIntyre , Alison Pattie , Lee Murphy , Rebecca M. Reynolds ,
       Rebecca Elliot , Ian S. Penton-Voak , Marcus R. Munafò , Kathryn L. Evans ,
     Jonathan R. Seckl , Joanna M. Wardlaw , Stephen M. Lawrie ,
















1 1 1 1
2 3 4
1 1 1 4
4 4 2 1
2 2 2 1 2
4 4 4 4
4 4 4 5
6 7 7 4
4 4 4











 25 Nov 2019,  :185 (First published: 4
)https://doi.org/10.12688/wellcomeopenres.15538.1
 25 Nov 2019,  :185 (Latest published: 4
)https://doi.org/10.12688/wellcomeopenres.15538.1
v1
Page 1 of 20

































Page 2 of 20
Wellcome Open Research 2019, 4:185 Last updated: 07 APR 2020
  Tina Habota ( )Corresponding author: tina.habota@abdn.ac.uk
  : Formal Analysis, Investigation, Project Administration, Writing – Original Draft Preparation, Writing – Review & Editing; Author roles: Habota T
: Formal Analysis, Investigation, Methodology, Writing – Original Draft Preparation, Writing – Review & Editing;  : Investigation,Sandu AL Waiter GD
Methodology, Writing – Review & Editing;  : Investigation, Methodology, Writing – Review & Editing;  : Methodology,McNeil CJ Steele JD
Supervision, Writing – Review & Editing;  : Investigation, Methodology, Writing – Review & Editing;  : Conceptualization,Macfarlane JA Whalley HC
Methodology, Writing – Review & Editing;  : Investigation, Writing – Review & Editing;  : Project Administration, Writing –Valentine R Younie D
Review & Editing;  : Investigation, Writing – Review & Editing;  : Data Curation, Formal Analysis, Project Administration,Crouch N Hawkins EL
Writing – Review & Editing;  : Investigation, Project Administration, Writing – Review & Editing;  : Investigation, Methodology,Hirose Y Romaniuk L
Writing – Review & Editing;  : Project Administration, Writing – Review & Editing;  : Investigation, Software, Writing – Review &Milburn K Buchan G
Editing;  : Investigation, Writing – Review & Editing;  : Investigation, Writing – Review & Editing;  : Investigation, ProjectCoupar T Stirling M Jagpal B
Administration, Writing – Review & Editing;  : Investigation, Project Administration, Writing – Review & Editing;  : Investigation,MacLennan B Priba L
Writing – Review & Editing;  : Formal Analysis, Investigation, Writing – Review & Editing;  : Investigation, Writing – Review &Harris MA Hafferty JD
Editing;  : Investigation, Writing – Review & Editing;  : Data Curation, Project Administration, Writing – Review & Editing; Adams MJ Campbell AI
: Methodology, Writing – Review & Editing;  : Methodology, Writing – Review & Editing;  : Project Administration,MacIntyre DJ Pattie A Murphy L
Writing – Review & Editing;  : Methodology, Writing – Review & Editing;  : Conceptualization, Methodology, Writing – Review &Reynolds RM Elliot R
Editing;  : Conceptualization, Methodology, Writing – Review & Editing;  : Conceptualization, Methodology, Writing –Penton-Voak IS Munafò MR
Review & Editing;  : Conceptualization, Funding Acquisition, Methodology, Writing – Review & Editing;  : Conceptualization,Evans KL Seckl JR
Funding Acquisition, Methodology, Writing – Review & Editing;  : Conceptualization, Funding Acquisition, Methodology, Writing –Wardlaw JM
Review & Editing;  : Conceptualization, Funding Acquisition, Writing – Review & Editing;  : Conceptualization, FundingLawrie SM Haley CS
Acquisition, Methodology, Writing – Review & Editing;  : Conceptualization, Funding Acquisition, Methodology, Writing – Review &Porteous DJ





















The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
 © 2019 Habota T  . This is an open access article distributed under the terms of the  , whichCopyright: et al Creative Commons Attribution License
permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
 Habota T, Sandu AL, Waiter GD   How to cite this article: et al. Cohort profile for the STratifying Resilience and Depression Longitudinally
(STRADL) study: A depression-focused investigation of Generation Scotland, using detailed clinical, cognitive, and neuroimaging
 Wellcome Open Research 2019,  :185 (assessments [version 1; peer review: 1 approved, 1 not approved] 4
)https://doi.org/10.12688/wellcomeopenres.15538.1
 25 Nov 2019,  :185 ( ) First published: 4 https://doi.org/10.12688/wellcomeopenres.15538.1
Page 3 of 20
Wellcome Open Research 2019, 4:185 Last updated: 07 APR 2020
Introduction
Why was the study set up?
Major depressive disorder (MDD) affects approximately 13% 
of the population at least once in their lifetime1, and remains 
a leading cause of economic burden and non-lethal global 
disability2,3 due to its recurrent or chronic nature. At present, 
MDD diagnosis is based on arbitrary and clinically heterogeneous 
criteria4. Consequently, and even with optimal management, 
much of the disability caused by MDD persists5 because of 
the absence of targeted disease-modifying treatments. The 
underlying pathophysiology of MDD is believed to be het-
erogeneous6, with genetic and environmental factors acting to 
influence disease expression. Thus, it is important for treat-
ment to shift from the current “trial and error” approach, towards 
personalised and preventative forms of treatment for individu-
als with markedly different disease mechanisms. However, 
progress in this area has been severely restricted because the 
aetiology of MDD is complex, and remains poorly understood.
STratifying Resilience and Depression Longitudinally 
(STRADL) aims to subtype MDD on the basis of its aetiology 
using detailed clinical, cognitive, and brain imaging assess-
ments. STRADL will examine the interaction between genetic 
and environmental factors that increase risk and occurrence 
of different MDD subtypes, and assess common and distinct 
mechanisms and clinical trajectories of MDD phenotypes. 
Additionally, STRADL aims to assess individual resilience, 
or the ability to adapt positively and ‘avoid’ psychopathology 
despite exposure to known risk factors such as stress, early-life 
adversity, and family history7.
STRADL was built on the Generation Scotland: Scottish Fam-
ily Health Study resource (GS:SFHS)8, which undertook its 
first major baseline assessments between 2006 and 2011. 
GS:SFHS is a population-based study of genetic health and 
complex disease in a cohort of 24,096 individuals, who have 
been extensively phenotyped for MDD and related traits. 
This cohort provides an important opportunity to study gene- 
environment interactions, and remains one of the richest sources 
of data available, incorporating linkage of existing phenotypic 
and genomic data, detailed lifestyle and socioeconomic charac-
terisation, extensive eHealth Record linkage9, and the inclusion 
of two longitudinal birth cohorts – the Walker birth cohort10, 
and Aberdeen Children of the 1950s (ACONF)11. The first 
wave of STRADL included depression-focused follow-up 
assessment of GS:SFHS, which involved remote question-
naires; study protocol and cohort characteristics are described 
elsewhere12. Here, we describe the second wave of STRADL, a 
depression-focused deep phenotyping face-to-face assessment, 
using detailed clinical and cognitive tests, and neuroimaging. 
The results describe the cohort profile and baseline 
questionnaire and cognitive data, and we provide a summary 
of key demographic data from the current wave of STRADL, 
compared to STRADL remote follow-up and wider GS:SFHS 
baseline assessment. A summary of all data available and the 
proportion of valid and useable data is also provided.
Methods
Who is in the cohort?
We aim to study people both with and without depression, 
and therefore our recruitment targeted the whole GS:SFHS 
population, not merely people with a depression history. Par-
ticipants in the Tayside and Grampian areas who had already 
taken part in GS:SFHS between 2006–2011, and who were 
eligible for re-contact, were sent a postal invitation by the 
University of Dundee Health Informatics Centre (HIC). Included 
in the invitation was a reply slip to indicate whether the par-
ticipant would be willing to undergo face-to-face assessment 
and brain magnetic resonance imaging (MRI), described here. 
Those who replied positively were contacted by telephone 
by a researcher at the most local recruitment centre. In Dundee 
(Tayside) recruitment targeted members of the Walker cohort, 
and in Aberdeen recruitment initially targeted members of 
ACONF, due to the rich early-life data already available for these 
cohorts.
In total, 5,649 potential participants were invited to take part 
in the study; 576 (10.2%) were members of ACONF; 1,103 
(19.5%) were members of the Walker cohort; and 3,970 (70.3%) 
were members of the wider GS:SFHS population. Out of these 
potential participants, 646 (11.4%) people declined participa-
tion at first point of contact with HIC, and we received no reply 
from 3,358 (59.4%) people, even after sending up to three 
reminders. Initially, 1,645 (29.1%) people responded posi-
tively; however, a further 170 (3.0%) declined once they were 
contacted by our research team or withdrew before consent-
ing. Recruitment ended in May 2019 and we consented and 
tested 1,188 (72.2%) of positive respondents across Aberdeen 
(n = 582) and Dundee (n = 606) sites. Figure 1 shows the recruit-
ment process and attrition.
What has been measured and when?
Table 1 shows all variables collected in STRADL face-to-face 
assessments, and those that were repetitions of the GS:SFHS 
baseline assessment and STRADL remote questionnaire 
follow-up. Before any new data were collected, participants 
signed a consent form permitting data and samples to be shared 
with other researchers through a secure data management 
system, and provided permission to be re-contacted in the future 
for additional research. Consent for linkage of participant data 
and samples to routine NHS records was previously obtained as 
part of the original GS:SFHS (05/S1401/89). All subsequent 
procedures were conducted following an independent, but linked, 
ethics application (14/SS/0039).
At each site participants attended three testing ‘stations’, which 
involved i) collection of clinical and questionnaire data, and 
biological samples ii) cognitive assessment, and iii) neuroim-
aging, the order of which varied at random between partici-
pants. Data from the clinical station were collected without a 
set order; however, cognitive tests were administered in the 
same order for each participant, and the MRI sequences also 
remained the same – except for one fMRI task, which was 
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counterbalanced (details described in section Brain magnetic 
resonance imaging). All measures were administered in accord-
ance with rigorous standard operating procedures based 
on best practice.
Clinical assessment
Medical history was updated from previous GS:SFHS base-
line assessment and any new diagnoses or medical episodes 
were recorded. General health and lifestyle data were also 
collected, as were the physical measurements of height, weight, 
two automated measures of blood pressure, and left- and right-
hand grip strength (using a Patterson Medical Jamar hand 
dynamometer). We collected laboratory samples for repeat 
genetic analysis and additional genomic analyses, and for 
analysis of epigenetic status including DNA methylation. 
Additionally, detailed questionnaire data were collected that will 
be used to test the structure of depressive symptoms and their 
association with each measure.
Laboratory samples. A small sample of hair was collected from 
the posterior vertex region for longitudinal cumulative corti-
sol. Cortisol assays from hair samples provide a more stable 
marker of chronic cortisol exposure compared to cross-sectional 
blood or urine samples, which show considerable diurnal 
variation13. Other available assays include cortisone, testoster-
one, progesterone, and dehydroepiandrosterone. Venepuncture 
was carried out using a butterfly needle kit. Blood was extracted 
into the following vacutainers types (analyses in parentheses): 
1) EDTA (Full blood count; FBC); 2) clot activator gel for serum 
separation (C-reactive protein CRP); 3) EDTA (DNA extrac-
tion); 4) 2 x Tempus RNA (RNA extraction); 5) EDTA (plasma 
biomarkers); 6) Lithium Heparin (plasma biomarkers). FBC and 
CRP samples were taken and sent to NHS laboratories for screen-
ing of clinically significant markers of anaemia and inflamma-
tion. When blood samples could not be collected, a saliva DNA 
collection kit (Oragene or GeneFiX) was used instead. These 
laboratory samples were temporarily stored at each collection 
Figure 1. STRADL recruitment flowchart.
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Table 1. List of novel and repeated variables collected in STRADL face-to-face assessment, compared 
to STRADL remote follow-up and GS:SFHS baseline assessment.
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site. RNA and blood DNA samples were stored at -80°C, and all 
others at -20°C, before being sent to the Edinburgh Clinical 
Research Facility at the University of Edinburgh for analysis 
and long-term storage. A summary of the completeness of 
these clinical data is shown in Table 2 and Table 3. FBC and 
CRP analysis are complete, and other blood and hair samples 
are in the process of being analysed.
Clinical interview and questionnaire data. All participants were 
assessed for a lifetime history of MDD. We used a research 
version of the Structured Clinical Interview for DSM-IV 
disorders (SCID)14 to assess symptoms of mood disorder (includ-
ing MDD and episodes of mania and hypomania), repeating 
the GS:SFHS baseline assessment. Diagnostic criteria were 
based on the Diagnostic and Statistical Manual of Mental 
Disorders (DSM-IV-TR). For participants who met full crite-
ria for MDD, we assessed if any episode had a post-partum 
onset, and if criteria for melancholic or atypical MDD subtypes 
were met. The research version of the SCID was designed to 
allow assessors to systematically evaluate individuals against 
the key DSM-IV-TR criteria for unipolar depression and 
bipolar disorder. The SCID has good reliability, and it is 
considered the “gold standard” in determining clinical diagnoses 
and their accuracy15.
Participants also completed a series of short questionnaires that 
assessed resilience, psychological well-being and mild psychi-
atric problems, and personality, some of which were repeated 
after first being completed for GS:SFHS (see Table 1). The 
Brief Resilience Scale (BRS)16 is a six-item questionnaire 
used as a measure of psychological resilience, or the ability to 
‘bounce back’ from stress. Participants were assessed for a life 
history of cannabis use using the Drug Use questionnaire devel-
oped for UK Biobank17. Those who used cannabis more than 
once were asked follow-up questions about the frequency and 
functional impact of their use. Three mood questionnaires were 
administered: the Mood Disorder Questionnaire (MDQ)18, 
which is a sensitive screen for bipolar spectrum disorders; the 
Quick Inventory of Depressive Symptomology (QIDS)19, which 
is a 16-item inventory designed to assess the severity of depres-
sive symptoms; and the Hospital Anxiety and Depression Scale 
(HADS)20 anxiety subscale (seven items) was used to screen for 
symptoms of anxiety. In addition, the General Health Ques-
tionnaire (GHQ)21, a 28-item test, was used to assess general 
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Table 2. Summary of demographic and background data, and 























Table 3. Summary of deep phenotype data available, and 
proportion valid data (n = 1,188).
Measurement %






























































psychological well-being on four scales: somatic symptoms; 
anxiety; social dysfunction; and depression. We used a Likert 
scoring system for the GHQ to calculate scores for each 
scale separately, as well as a total score.
We administered two measures that assess core personality 
traits: we used the neuroticism and extraversion scales from 
the Eysenck Personality Questionnaire – Revised Short Form 
(EPQ-R)22, each of which has 12 items; and the International Per-
sonality Item Pool (IPIP), Five-Factor Personality Inventory23, 
which is a 50-item questionnaire that assesses the following 
core personality traits: extraversion; agreeableness; consci-
entiousness; emotional stability (the reverse of neuroticism); 
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and imagination/intellect (similar to openness). Additionally, 
the General Causality Orientations Scale24, which con-
sists of 12 vignettes describing scenarios to determine each 
person’s orientation of causality25, was used to assess one’s 
inclination towards being motivated autonomously, externally, 
or passively.
Finally, we assessed early-life adversity (childhood or adoles-
cent abuse or neglect) using the Childhood Trauma Question-
naire (CTQ)26. This is a 28-item retrospective inventory that 
assesses three areas of abuse (emotional, physical, and sex-
ual) and two areas of neglect (emotional and physical). The 
CTQ also includes a minimisation/denial scale that identifies 
potential underreporting of maltreatment. A mean score was 
calculated for each measure by totalling the item responses, 
with appropriate reverse scoring (e.g., GHQ, BRS). Higher scores 
represent higher levels of psychological distress, personality 
trait, or childhood trauma, except for the BRS where higher 
scores indicate greater resilience. Scoring and interpretation of 
data were based on the administration manual of each test.
Cognitive testing
The cognitive tests that were applied will be used to assess 
the cognitive phenotype of depression, and whether genetic 
risk variants are related to impairment in specific cognitive 
domains. As with the questionnaire data, some cognitive tests 
were also repetitions of the GS:SFHS baseline assessment 
(Table 1). We included “cold” (emotion-independent) and “hot” 
(emotion-laden) cognitive tests, given growing evidence for 
distinct and interacting relationships between depression and 
measures of hot and cold cognition27.
The cold cognitive test battery included validated and widely 
used cognitive tests that measure crystallised- and fluid-type 
cognitive tasks. The Mill Hill Vocabulary test28 was used as 
a measure of acquired verbal intelligence, and is an estimate 
of ‘crystallised intelligence’ and peak cognitive ability. The 
Controlled Oral Word Association task29 was used as a meas-
ure of phonemic verbal fluency using three letters (C, F, and 
L). The Digit Symbol Coding subtest from the Wechsler Adult 
Intelligence Scale-III30 was used to measure information process-
ing speed. A United Kingdom version of the Logical Memory 
subtest from the Wechsler Memory Scale-III31 was used to 
assess verbal memory and provided a measure of immediate and 
delayed verbal declarative recall. Total scores were created for 
each cognitive test by adding the number of correct responses; 
higher scores indicate better performance. The Matrix Reason-
ing test, a paper adaptation of the computerised version from 
the COGNITO psychometric examination32, was used to 
measure perceptual organisation and visuospatial logic. A sum-
mary of all mood, personality, and cognitive data and their 
completeness is shown in Table 3.
Three ‘hot’ cognitive measures were administered on a touch-
screen laptop computer. The first task – the Bristol Emotion 
Recognition Test – consisted of 96 trials (16 of each emotion) 
that assessed recognition of six basic human facial emotions 
(happiness, anger, sadness, disgust, surprise, and fear), and biases 
in the attribution of emotion. The Affective Go/No-Go task 
comprised 120 trials that assessed behavioural inhibition using 
facial emotional stimuli (happy, sad, and neutral expressions). 
Finally, given evidence for impairments in reward processing 
in depression33, we also included a modified version of the 
Cambridge Gambling Task, which assesses decision-making, 
risk-taking behaviour, and reward processing (30 trials). 
These three tests are described in detail elsewhere34,35.
Brain magnetic resonance imaging
The neuroimaging protocol will allow analysis of potential risk 
factor relationships with brain structure and function, and test 
neurobiological mechanisms that are associated with depres-
sive symptoms and resilience. In Aberdeen, participants were 
imaged on a 3T Philips Achieva TX-series MRI system (Philips 
Healthcare, Best, Netherlands) with a 32 channel phased-
array head coil and a back facing mirror (software version 
5.1.7; gradients with maximum amplitude 80 mT/m and maxi-
mum slew rate 100 T/m/s). A projector and “Presentation” 
(Neurobehavioural Systems Inc, Berkeley, CA, USA) ver-
sion 18.1 were used for the presentation of task-based fMRI. In 
Dundee, participants were scanned using a Siemens 3T Prisma-
FIT (Siemens, Erlangen, Germany) with 20 channel head 
and neck phased array coil and a back facing mirror (Syngo 
E11, gradient with max amplitude 80 mT/m and maximum 
slew rate 200 T/m/s). A magnetic resonance compatible LCD 
screen was used to display fMRI (NordicNeuroLab, Bergen, 
Norway) task stimuli using “Presentation” version 20.0.
Both centres used the same protocol including structural and 
functional sequences. The structural sequences collected were 
as follows: 3D T1-weighted fast gradient echo with magneti-
sation preparation; 3D T2-weighted fast spin echo; 3D Fluid 
Attenuation Inversion Recovery (FLAIR); Diffusion Ten-
sor Imaging (DTI); and Susceptibility Weighted Imaging 
(SWI) or T2*-weighted gradient echo. The functional sequences 
comprised of two task-based fMRI tasks and a resting state 
fMRI sequence. The sequence parameters, as well as the order 
of acquisitions, are presented in Table 4.
T1-weighted images of the brain were used to assess brain 
regional volumes, cortical thickness, gyrification index, voxel-
based morphometry analysis, certain lesions such as lacunes, 
cortical and larger subcortical infarcts, and will also serve as the 
basis for co-registration with other sequences. A 3D T2-weighted 
sequence was used to detect lacunes, perivascular spaces, corti-
cal and subcortical infarcts, and other morphological measure-
ments, such as hippocampal subfield extraction. A 3D FLAIR 
was used to detect white matter hyperintensities. SWI data, 
for the determination of brain microbleeds, basal ganglia min-
eralisation, and cortical superficial siderosis, were acquired 
using a 3D multi-echo gradient-echo sequence in Aberdeen 
and a single-echo protocol in Dundee. Phase and magnitude 
data were saved for the calculation of T2* relaxation. All vas-
cular lesions listed above are defined in the Standards for 
Reporting Vascular changes on Neuroimaging standards36. All 
structural images were reviewed by a neuroradiologist for 
visual analysis of vascular changes and incidental findings. 
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Table 4. Magnetic resonance imaging (MRI) sequences and their characteristics acquired in Aberdeen and Dundee.
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Whole-brain DTI were recorded to allow assessment of micro-
structural integrity of white matter including fibre direction and 
structural connectivity. This protocol reflects established 
neuroimaging approaches as used in several large cohort 
studies of ageing and of cerebrovascular diseases37,38.
There were two task-based fMRI sequences: an implicit emo-
tional processing task (fearful versus neutral faces), and a 
modified version of an instrumental reward task with an addi-
tional choice value component. Both of these, as well as resting 
state fMRI, were acquired at 30 degrees away from the anterior 
commisure–posterior commisure (AC-PC), towards the coro-
nal plane. The fearful faces from NimStim39 facial stimuli set 
assessed emotional-limbic circuitry through a block fMRI 
design, and measures the brain’s neural responses to the 
viewing of fearful faces in the absence of learning. In order 
to avoid a gender bias of the images, two versions of the 
tasks were used, counterbalanced across participants. The 
Reward task measured reward-related brain activity using 
an event-related fMRI design in a reinforcement learning con-
text. The resting state fMRI was used to investigate functional 
connectivity and brain networks.
Results
What are the key findings?
Here, we report findings for the complete data set including 
1,188 participants. Table 5 shows some demographic simi-
larities and differences between the current STRADL cohort 
and existing samples. More specifically, the median age of the 
STRADL sample was 62 years, which is older compared to both 
STRADL remote follow-up and wider GS:SFHS populations. 
Gender distributions were comparable to existing data, with 59% 
being female, and our sample had higher levels of education 
(university-level education = 40%), compared to existing data. 
Furthermore, based on SCID interviews, a higher proportion 
of STRADL participants were diagnosed with a lifetime his-
tory of mood disorder (30.7%), compared to GS:SFHS (13.2%). 
Out of the total sample, 28.8% received a diagnosis of MDD, 
and a further 1.9% of bipolar disorder. Recurrent mood dis-
order was present in 72.7%, and melancholic features (56%) 
were dominant in the group. Of those with a diagnosis, 71% 
were female. Overall, however, the cohort was of good psycho-
logical health at the time of assessment, as indicated by mean 
scores on the GHQ, HADS, and QIDS (Table 6), which fell 
below the thresholds for the presence of psychological distress. 
Cognitive scores across all measures were normally distrib-
uted. Psychological health, personality, and cognitive scores are 
presented in Table 6.
Discussion
Strengths and limitations
STRADL data have been robustly collected on a wide range 
of key phenotypes that allow epidemiological study of depres-
sion and resilience in a population-based cohort. The MRI 
and detailed depression phenotyping protocol described 
here was cross-sectional; however, STRADL can provide 
longitudinal measures of cognition, personality, and psycho-
logical health. This is because many of the cognitive tests 
applied in STRADL are deliberately the same as those used at 
the GS:SFHS baseline assessment, as well as some personal-
ity and mood measures, as shown in Table 1. The availabil-
ity of repeated cognitive and questionnaire testing allows us to 
assess potential determinants of change in cognition and psy-
chological health. Similarly, routine NHS data, and ACONF and 
Walker cohorts’ early-life variables, are linked to STRADL data, 
providing further opportunities for longitudinal predictors on 
depression and resilience across the full life-course. Limita-
tions of this cohort are that, as with many longitudinal popula-
tion studies, participants were more likely to be of good health, 
and come from more advantaged backgrounds such as higher 
Table 5. Comparison of demographic data between STRADL face-to-face assessment, 
STRADL remote follow-up, and wider GS:SFHS baseline assessment.










   Male 62 54 47
   Female 61 52 48
Gender (%) (female) 59 62 59
Employment (%) (those aged up to 75 years)
   Unemployed 3 4 2
   Retired 32 18 15
   Employed 65 71 63
Education (%)
   University-level degree 40 37 33
   No qualification 25 7 5
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education and better socioeconomic circumstances than the 
population in general – findings that are similar to GS:SFHS 
and STRADL remote follow-up cohort profiles8,12, and UK 
Biobank17. Notably, however, participants from a range of 
health and demographic backgrounds were represented in this 
group.
Ethical approval and consent
Ethical approval for the study was obtained from the Scotland 
A Research Ethics Committee (REC reference number 
14/55/0039) and the local Research and Development offices. All 
participants provided written informed consent prior to the 
collection of any data or samples.
Table 6. Baseline questionnaire and cognitive measures (n = 1,188).
Variable Maximum score Mean (SD) Range
Questionnaire data
BRS  30 21.46 (4.89) 0–30
HADS – anxiety  21 4.15 (3.52) 0–20
QIDS – total  27 4.64 (3.65) 0–22
General Health Questionnaire
     GHQ – somatic symptoms 21 3.95 (3.23) 0–21
     GHQ – anxiety 21 3.24 (3.32) 0–21
     GHQ – social dysfunction 21 7.18 (2.01) 0–21
     GHQ – depression 21 0.81 (2.39) 0–21
     GHQ – total 84 15.15 (8.56) 2–75
EPQ-R – neuroticism 12 3.40 (3.19) 0–12
EPQ-R – extraversion 12 7.05 (3.80) 0–12
International Personality Item Pool
     IPIP – extraversion 50 31.17 (7.45) 11–50
     IPIP – agreeableness 50 41.50 (5.34) 20–50
     IPIP – conscientiousness 50 37.62 (6.04) 11–50
     IPIP – emotional stability 50 33.58 (7.85) 10–50
     IPIP – intellect  50 34.78 (5.58) 11–50
Childhood Trauma Questionnaire
     CTQ – physical abuse  25 6.11 (2.41) 0–25
     CTQ – sexual abuse 25 6.04 (3.57) 0–25
     CTQ – emotional abuse 25 7.00 (3.47) 0–25
     CTQ – physical neglect 25 6.35 (2.36) 0–21
     CTQ – emotional neglect 25 8.56 (4.21) 0–25
Cognitive data
Logical Memory test – immediate 25 16.34 (3.63) 4–24
Logical Memory test – delayed 25 15.40 (3.91) 3–24
Logical Memory test – combined 50 31.74 (7.29) 9–48
Digit Symbol Coding 133 68.15 (15.24) 24–116
Verbal fluency test – combined - 42.98 (12.02) 12–88
Mill Hill Vocabulary test 44 31.56 (4.09) 16–44
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Data availability
All data underlying the results are available as part of 
the article and no additional source data are required.
A phenotype data dictionary is available and open access 
genome-wide association study summary statistics can be 
downloaded. Non-identifiable information from the GS:SFHS 
cohort is available to researchers in the UK and to interna-
tional collaborators through application to the Generation 
Scotland Access Committee (access@generationscotland.org) 
and through the Edinburgh Data Vault (https://doi.org/10.7488/
8f68f1ae-0329-4b73-b189-c7288ea844d7). Generation 
Scotland operates a managed data access process including 
an online application form, and proposals are reviewed by the 
Generation Scotland Access Committee. The data and samples 
collected by the STRADL study have been incorporated in the 
main Generation Scotland dataset and governance process. 
Summary information to help researchers assess the feasibility and 
statistical power of a proposed project is available on request by 
contacting resources@generationscotland.org.
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is said to be to “examine the interaction between genetic and environmental factors that
increase risk and occurrence of different MDD subtypes, and assess common and distinct
mechanisms and clinical trajectories of MDD phenotypes. Additionally, STRADL aims to
assess individual resilience, or the ability to adapt positively and ‘avoid’ psychopathology
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